期刊文献+

omapatrilat对5/6肾切除大鼠肾小管间质病变的影响 被引量:4

Effects of omapatrilat on renal tubulointerstitial fibrosis in 5/6 subtotal nephrectomized rats
原文传递
导出
摘要 目的 观察血管肽酶抑制剂omapatrilat对5/6肾切除大鼠肾衰模型肾小管间质 病变的影响,探索防治肾小管间质纤维化的新途径。方法建立5/6肾切除肾衰大鼠模型,随 机分成手术对照组、Omap 10 mg组(omapatrilat 10 mg·kg-1·d-1)和Omap 40 mg组(omapatrilat 40 mg·kg-1·d-1),另设假手术组和正常对照组。12周后观察比较各组间大鼠尾部动脉收缩压、 肾功能、肾小管间质纤维化水平(HE、Masson、PAS和PASM染色,半定量分析)。结果(1)omapatrilat 能明显降低5/6肾切除肾衰竭大鼠血压水平[(153.67±9.69)mmHg比(192.00±10.45)mmHg, P<0.01],且Omap 40 mg组降压效果明显优于Omap 10 mg组[(142.50±11.14)mmHg比 (153.67+9.69)mmHg,P<0.05];(2)omapatrilat能改善5/6肾切除肾衰竭大鼠肾功能[Scr(61.00±15.50) μmol/L比(97.00±34.10)μmol/L,P<0.01:BUN(19.38±3.65)mmol/L比(30.23±9.31)mmol/L, P<0.01 1:(3)omapatrilat可减轻肾小管间质纤维化程度(2.0±0.63比2.83±0.55,P<0.05),但 40 mg和10 mg两剂量组差异无统计学意义。结论 omapatrilat能明显降低5/6肾切除大鼠血 压水平.显著改善其肾功能及延缓肾小管间质纤维化进展。 Objective To investigate the effect of vasopeptidase inhibitors (VPi) omapatrilat on renal tubulointerstitial fibrosis of 5/6 subtotal nephrectomized rats and to explore new prevention and treatment of renal lubulointerstitial fibrosis.Methods The renal subtotal ablation model was established by surgical 5/6 renal resection in male SD rats.Five animal groups included(1)STN group (subtotal nephreclomy); (2)Omap 10 mg group (10 mg·kg-1·d-1); (3)Omap 40 mg group (40 mg·kg-1·d-1) ; (4)Sham group and (5)Nornial control. Systolic arterial BP and renal function were measured periodically.Animals were sacrificed at the end of the 12th week after operation. Tubulointerstitial injury was scored semiquantitatively by morphological analysis (HE, Masson, PAS and PASM stain). Results Significant tubulointerstitial injury was noted in the STN group compared with normal group and sham group (P<0.01). Blood pressure, tubulointerstitial injury and renal function were improved in omapatrilat treated groups as compared to STN group. [BP (153.67±9.69) mmHg vs (192.00±10.45)mmHg,P<0.01;tubulointerstitial injury 2.00±0.63 vs 2.83±0.55 ,P<0.05 and Scr (61.00±15.52)μmol/L vs (97.00±34.10)μmol/L, P<0.01]. Conclusion Omapatrilat can markedly decrease blood pressure and obviously ameliorate tubulointerstitial fibrosis and renal function.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2005年第4期204-206,共3页 Chinese Journal of Nephrology
基金 国家自然科学基金(30270613)上海市科学技术委员会重大项目(03JC14084)
  • 相关文献

参考文献16

  • 1Nawarskas JJ, Anderson JR. Omapatrilat: a unique new agent for the treatment of cardiovascular disease. Heart Dis, 2000,2: 266-274 被引量:1
  • 2Husereau DR. Omapatrilat for the management of heart failure and hypertension. Issues Emerg Health Technol, 2001,17:1-4. 被引量:1
  • 3Varagic J, Susic D, Slama M, et al. Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.J Cardiovasc Pharmacol Ther, 2003,8: 167-174. 被引量:1
  • 4Mezzano SA, Droguett MA, Burgos ME,et al.Overexpression of chemokines,fibrogenic cytokines,and myofibroblasts in human membranous nephropathy. Kidney Int, 2000,57:147-158. 被引量:1
  • 5章斌,王伟铭,史浩,赵青,陈楠.缬沙坦和雷米普利对5/6肾切除大鼠肾间质微血管的作用[J].肾脏病与透析肾移植杂志,2003,12(1):28-31. 被引量:7
  • 6Cao Z, Burrell LM, Tikkanen I,et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int, 2001,60: 715-721. 被引量:1
  • 7Xu J, Carretero OA, Liu YH, et al. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail,2004,10:83-89. 被引量:1
  • 8Ye VZ, Hodge G, Yong JL, et al. Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension. Eur J Pharmacol, 2004,485: 235-242. 被引量:1
  • 9Cases A. Omapatrilat: clinical pharmacology. Drugs Today (Barc ),2000,36: 817-828. 被引量:1
  • 10Neal B, MacMahon S, Ohkubo T, et al. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst,2002,3: 270-276. 被引量:1

二级参考文献15

  • 1Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol, 1996,7:2 495 被引量:1
  • 2Fine LG, Orphanides C, Norman JT. Progressive renal disease. The chronic hypoxia hypothesis. Kidney Int, 1998,65: S74 被引量:1
  • 3Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int, 2000,58:2 351 被引量:1
  • 4Bohle A, Mackensen-Haen S, Wehrmann M.Significance of post-glomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res, 1996,19:191 被引量:1
  • 5Kang DH, Joly AH, Oh SW. Impaired angiogenesis in the remnant kidney model(1) .Potential role of vascular endothelial growth factor and thrombospondin-1. J An Soc Nephrol, 2001,12:1 434 被引量:1
  • 6Choi YJ,Chakraborty S,Nguyen V.Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: Altered expression of vascular endothelial growth factor. Hum Pathol,2000,31:1 491 被引量:1
  • 7Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin Ⅱ and fibrosis. Hypertension,2001,38(Part 2) :635 被引量:1
  • 8Klahr S, Morrissey JJ. Comparative study of ACE inhibitors and angiotensin Ⅱ receptor antagonists in interstitial scarring . Kidney Int,1997,52(Suppl): s111 被引量:1
  • 9Ruiz-Ortega M, Loregzo O, Ruperez M. Role of the Renin-Angiotensin System in vascular diseases. Hypertnsion, 2001,38:1 382 被引量:1
  • 10Dimmeler s, Rippmann V, Weiland U. Angiotensin Ⅱ induces apoptosis of human endothelial cells . Circulation Res, 1997,81:970 被引量:1

共引文献6

同被引文献51

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部